Sumitomo Chemical has developed a unique manufacturing technology for producing oligonucleotides at commercial scale with high yield and purity, which gives in particular for long oligonucleotides (60 – 100 mer and more) a superior performance.  Due to the high interest from the market in our capabilities, Sumitomo Chemical is investing in a new manufacturing facility at its Oita Works, Japan, which will be commercially ready in June 2023.  With its focus on life sciences, Sumitomo Chemical is endeavoring to contribute to better lives for patients all over the world by investing in this cutting-edge technology to support the development of gene-editing drugs.  For inquiries, please contact us at SCE-pharmachem@sumitomo-chemical.eu.